Triple-Drug cocktail targets tough penile cancer
NCT ID NCT07384416
First seen Feb 03, 2026 · Last updated Apr 30, 2026 · Updated 14 times
Summary
This study tests a three-drug combination (QL1706, lenvatinib, and nab-paclitaxel) in 47 people with advanced penile cancer that has come back or not responded to prior treatment. The goal is to see if the combination can shrink tumors or slow cancer growth. All participants receive the same treatment and are monitored for side effects and tumor changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PENILE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.